Company Overview - Xiansheng Zaiming Pharmaceutical Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange on January 9, with Morgan Stanley and CICC as joint sponsors [1] - The company was established in 2020, focusing on the research, development, and commercialization of innovative cancer drugs [1] - It has five commercialized innovative drugs and over 15 high-potential candidates in clinical and IND application preparation stages, along with multiple discovery projects [1] Market Position - According to a report by Aoyishi Consulting, by 2025, the company is expected to complete three out-licensing transactions, ranking first in the number of oncology asset transactions and fourth in total transaction value among Chinese biopharmaceutical companies [1]
新股消息 | 先声再明递表港交所
智通财经网·2026-01-10 09:49